CRTX insider filings
Cortexyme, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-07-01. Screen CRTX transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for CRTX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Cortexyme, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-07-01 | 4 | Monohon Ted — Chief Accounting Officer & VP | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Bray June — Director | Grant/award (A): 54,000 (derivative) @ $0 | EDGAR |
| 2022-06-09 | 4 | Lamond David — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2022-06-09 | 4 | McLoughlin Margaret — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2022-06-09 | 4 | Senner Christopher J. — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2022-06-09 | 4 | RYAN UNA S — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2022-06-08 | 4 | Holsinger Leslie — EVP, Preclinical Development | Tax withholding (F): 10,920 @ $2.86 | EDGAR |
| 2022-06-08 | 4 | McDowell Caryn Gordon — Chief Legal & Adm. Officer | Tax withholding (F): 6,700 @ $2.86 · Sale (S): 10,800 @ $2.86 | EDGAR |
| 2022-06-08 | 4 | Monohon Ted — Chief Accounting Officer & VP | Tax withholding (F): 1,529 @ $3.12 | EDGAR |
| 2022-05-27 | 4/A | Hannah Brendan — Chief Business Officer | Grant/award (A): 113,569 @ $0 | EDGAR |
| 2022-05-27 | 4/A | Smith Karen L. — Chief Medical Officer | Grant/award (A): 170,354 @ $0 | EDGAR |
| 2022-05-27 | 4/A | Thye Dirk — Chief Executive Officer, Director | Grant/award (A): 216,322 @ $0 | EDGAR |
| 2022-05-23 | 4 | Lamond David — Director | Grant/award (A): 200,002 | EDGAR |
| 2022-05-23 | 4 | Hannah Brendan — Chief Business Officer | Grant/award (A): 16,224 · Grant/award (A): 103,500 (derivative) · Grant/award (A): 353,656 (derivative) @ $0 | EDGAR |
| 2022-05-23 | 4 | Smith Karen L. — Chief Medical Officer | Grant/award (A): 24,336 · Grant/award (A): 151,799 (derivative) · Grant/award (A): 1,365,449 (derivative) @ $0 | EDGAR |
| 2022-05-23 | 4 | Thye Dirk — Chief Executive Officer, Director | Grant/award (A): 64,589 · Grant/award (A): 206,391 (derivative) · Grant/award (A): 1,979,650 (derivative) @ $0 | EDGAR |
| 2022-05-23 | 4 | Low Philip S — Director | Grant/award (A): 455,309 · Grant/award (A): 63,974 · Grant/award (A): 22,058 (derivative) @ $0 | EDGAR |
| 2022-03-16 | 4 | Sabbagh Marwan — Director | Grant/award (A): 22,058 (derivative) @ $0 | EDGAR |
| 2022-03-04 | 4 | McDowell Caryn Gordon — Chief Legal & Adm. Officer | Grant/award (A): 140,000 @ $0 | EDGAR |
| 2022-03-04 | 4 | Holsinger Leslie — EVP, Preclinical Development | Grant/award (A): 155,500 @ $0 | EDGAR |
| 2022-03-04 | 4 | Detke Michael J. — Chief Medical Officer | Grant/award (A): 140,000 @ $0 | EDGAR |
| 2022-03-04 | 4 | Monohon Ted — Chief Accounting Officer & VP | Grant/award (A): 34,000 @ $0 | EDGAR |
| 2022-03-04 | 4 | LOWE CHRISTOPHER P. — Interim CEO, COO & CFO | Grant/award (A): 175,000 @ $0 | EDGAR |
| 2022-01-05 | 4 | Lynch Casey — Chief Executive Officer, Director | Grant/award (A): 440,000 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | McDowell Caryn Gordon — Chief Legal & Adm. Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Holsinger Leslie — EVP, R&D | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Dominy Stephen S. — Chief Scientific Officer, Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Detke Michael J. — Chief Medical Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Monohon Ted — Chief Accounting Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | LOWE CHRISTOPHER P. — COO & Chief Financial Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2021-11-19 | 4 | Lynch Casey — Chief Executive Officer, Director | Option exercise (M): 60,000 @ $0.46 · Option exercise (M): 60,000 (derivative) @ $0 | EDGAR |
| 2021-11-16 | 4 | LOWE CHRISTOPHER P. — COO & Chief Financial Officer | Option exercise (M): 30,000 @ $2.23 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2021-11-12 | 4 | Dominy Stephen S. — Chief Scientific Officer, Director | Purchase (P): 763 @ $14.40 | EDGAR |
| 2021-10-12 | 4 | McLoughlin Margaret — Director | Option exercise (M): 1,000 @ $17 · Sale (S): 1,000 @ $88.93 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2021-10-07 | 4 | LOWE CHRISTOPHER P. — COO & Chief Financial Officer | Option exercise (M): 4,963 @ $54.85 · Sale (S): 4,963 @ $98.50 · Option exercise (M): 4,963 (derivative) @ $0 | EDGAR |
| 2021-08-18 | 4 | McLoughlin Margaret — Director | Option exercise (M): 6,000 @ $17 · Sale (S): 3,056 @ $94.55 · Sale (S): 1,044 @ $95.57 · Sale (S): 1,429 @ $96.51 · Sale (S): 423 @ $97.55 · Sale (S): 48 @ $98.90 · +1 more | EDGAR |
| 2021-08-18 | 4 | LOWE CHRISTOPHER P. — COO & Chief Financial Officer | Option exercise (M): 22,000 @ $2.23 · Sale (S): 9,158 @ $94.23 · Sale (S): 7,335 @ $95.02 · Sale (S): 2,330 @ $96.32 · Sale (S): 1,100 @ $97.28 · Sale (S): 2,077 @ $98.90 · +3 more | EDGAR |
| 2021-08-12 | 4 | Detke Michael J. — Chief Medical Officer | Option exercise (M): 10,000 @ $2.23 · Sale (S): 10,000 @ $100 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2021-07-07 | 4 | Detke Michael J. — Chief Medical Officer | Option exercise (M): 12,600 @ $2.23 · Sale (S): 32,313 @ $53.43 · Sale (S): 8,260 @ $53.91 · Sale (S): 288 @ $55.01 · Option exercise (M): 17,400 @ $2.23 · Sale (S): 3,934 @ $53.24 · +6 more | EDGAR |
| 2021-06-30 | 4 | LOWE CHRISTOPHER P. — COO & Chief Financial Officer | Option exercise (M): 20,000 @ $2.23 · Sale (S): 7,724 @ $53.39 · Sale (S): 7,079 @ $54.13 · Sale (S): 4,153 @ $55.11 · Sale (S): 1,044 @ $56.16 · Option exercise (M): 30,000 @ $2.23 · +2 more | EDGAR |
| 2021-06-29 | 4 | McLoughlin Margaret — Director | Sale (S): 200 @ $55.01 · Sale (S): 250 @ $55.03 · Sale (S): 100 @ $55.73 | EDGAR |
| 2021-06-17 | 4 | McLoughlin Margaret — Director | Grant/award (A): 11,029 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | Lamond David — Director | Grant/award (A): 11,029 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | Senner Christopher J. — Director | Grant/award (A): 11,029 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | RYAN UNA S — Director | Grant/award (A): 11,029 (derivative) @ $0 | EDGAR |
| 2021-05-12 | 4 | Lynch Casey — Chief Executive Officer, Director | Sale (S): 13,584 @ $33.75 · Sale (S): 9,918 @ $34.89 · Sale (S): 6,315 @ $35.81 · Sale (S): 183 @ $36.73 | EDGAR |
| 2021-03-24 | 4 | Lamond David — Director | Purchase (P): 50,000 @ $33.77 | EDGAR |
| 2021-03-23 | 4 | Lamond David — Director | Gift (G): 1,534,720 @ $0 | EDGAR |
| 2021-03-23 | 4 | Lynch Casey — Chief Executive Officer, Director | Sale (S): 11,211 @ $35.10 · Sale (S): 18,089 @ $35.85 · Sale (S): 300 @ $36.58 · Sale (S): 400 @ $36.60 | EDGAR |
| 2021-03-05 | 4 | Lamond David — Director | Purchase (P): 16,621 @ $34.28 · Purchase (P): 13,310 @ $35 · Purchase (P): 15,969 @ $36.34 · Purchase (P): 4,100 @ $36.86 | EDGAR |
Recent 8-K events — Cortexyme, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-19 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-06 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-09-14 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-04 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-08-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-08-17 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=CRTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs